DFDA

Ruxolitinib Cream (Opzelura)

Treatment for Vitiligo

Typical Dosage: Apply thin layer twice daily to affected areas up to 20% BSA

Effectiveness
75%
Safety Score
60%
Clinical Trials
1
Participants
1.2K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
Apply thin layer twice daily to affected areas up to 20% BSA
Time to Effect
3-6 months
Treatment Duration
Lifetime
Evidence Quality
HIGH
Number Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$23,000
Monitoring:$300
Side Effect Mgmt:$100
Total Annual:$23,400
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATE
ICER
$119,726/QALY
QALYs Gained
0.25
Outcome-Based Costs
Cost per Responder
$58,500
Cost per Remission
$234,000
Ruxolitinib Cream (Opzelura) Outcomes

for Vitiligo

Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+40%
Remission Rate
+10%
Common Side Effects
Acne
+20%
Application site pruritus
+10%
Nasopharyngitis
+5%

Sources:

fda.gov
incyte.com
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
3 active trials recruiting for Ruxolitinib Cream (Opzelura) in Vitiligo

Efficacy and Safety of Ruxolitinib Cream in Chinese Children Aged 2-11 Years With Non-segmental Vitiligo

NCT07595939NOT YET RECRUITINGPHASE3
View Study
20 participants
INTERVENTIONAL
Hangzhou, China
Started: Jun 1, 2026

Topical Ruxolitinib Evaluation in Immune-related Vitiligo-like Depigmentation

NCT07725432ACTIVE NOT RECRUITINGPHASE2
View Study
34 participants
INTERVENTIONAL
Zurich, Switzerland
Started: Jul 25, 2024

Ruxolitinib Cream Combined With Corticosteroids for Progressive Non-Segmental Vitiligo: A Multicenter Real-World Study

NCT07673640RECRUITING
View Study
300 participants
OBSERVATIONAL
Shenzhen, China +19 more
Started: Jul 2, 2026
Completed Clinical Trials
1 completed trial for Ruxolitinib Cream (Opzelura) in Vitiligo

A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo

NCT05750823COMPLETEDPHASE2
View Study
49 participants
INTERVENTIONAL
Fremont, United States +12 more
Started: Apr 11, 2023